Historical role of alpha-1-antitrypsin deficiency in respiratory and hepatic complications

被引:14
作者
Zuo, Li [1 ]
Pannell, Benjamin K. [1 ]
Zhou, Tingyang [1 ,2 ]
Chuang, Chia-Chen [1 ,2 ]
机构
[1] Ohio State Univ, Sch Hlth & Rehabil Sci, Radiol Sci & Resp Therapy Div, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Interdisciplinary Biophys Grad Program, Columbus, OH 43210 USA
关键词
COPD; Disease; Elastase; Lung; Therapy; ALPHA(1)-ANTITRYPSIN DEFICIENCY; MOLECULAR-BASIS; SERUM ALPHA-1-ANTITRYPSIN; ANTITRYPSIN DEFICIENCY; LIVER-DISEASE; LUNG-FUNCTION; EMPHYSEMA; INHIBITOR; GENE; POLYMERIZATION;
D O I
10.1016/j.gene.2016.01.004
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Alpha-1-antitrypsin (AAT) deficiency is a heritable disease that is commonly associated with complications in the respiratory and hepatic systems. AAT acts as a regulatory enzyme that primarily inhibits neutrophil elastase activity thus protecting tissues from proteolytic damage after inflammation. This paper provides a historical review of the discovery, classification, phenotypic expression, and treatment of AAT deficiency. While its pattern of inheritance has been long understood, the underlying mechanism between AAT deficiency and related diseases remains to be elucidated. Most commonly, MT deficiency is associated with the development of emphysema in the lungs as well as various liver injuries. Cigarette smoke has been shown to be particularly detrimental in AAT deficient individuals during the development of lung disease. Therefore, understanding familial history may be beneficial when educating patients regarding lifestyle choices. While numerous AAT deficient phenotypes exist in the human populations, only specific variants have been proven to markedly predispose individuals to lung and liver disorders. The exact relationship between AAT levels and the aforementioned diseases is an essential area of further research. It is imperative that clinicians and researchers alike strive to standardize diagnostic criteria and develop safe and effective therapies for this genetic disease. (C) 2016 Elsevier B.V. All rights reserved.
引用
收藏
页码:118 / 122
页数:5
相关论文
共 68 条
[1]  
[Anonymous], GSTF JBIO
[2]   Estimated numbers and prevalence of PI*S and PI*Z alleles of α-antitrypsin deficiency in European countries [J].
Blanco, I ;
de Serres, FJ ;
Fernandez-Bustillo, E ;
Lara, B ;
Miravitlles, M .
EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (01) :77-84
[3]  
BRANTLY M, 1988, AM J MED, V84, P13
[4]   Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 α1-antitrypsin (AAT) vector in AAT-deficient adults [J].
Brantly, Mark L. ;
Spencer, L. Terry ;
Humphries, Margaret ;
Conlon, Thomas J. ;
Spencer, Carolyn T. ;
Poirier, Amy ;
Garlington, Wendy ;
Baker, Dawn ;
Song, Sihong ;
Berns, Kenneth I. ;
Muzyczka, Nicholas ;
Snyder, Richard O. ;
Byrne, Barry J. ;
Flotte, Terence R. .
HUMAN GENE THERAPY, 2006, 17 (12) :1177-1186
[5]   Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease [J].
Brode, Sarah K. ;
Ling, Simon C. ;
Chapman, Kenneth R. .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2012, 184 (12) :1365-1371
[6]   DETERMINATION OF ALPHA-1-ANTITRYPSIN PHENOTYPES AND M-SUBTYPES BY ISOELECTRIC-FOCUSING IN IMMOBILIZED PH GRADIENTS [J].
BROOKS, KP ;
IAMMARINO, RM .
CLINICAL BIOCHEMISTRY, 1985, 18 (05) :280-284
[7]   Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z:: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency [J].
Burrows, JAJ ;
Willis, LK ;
Perlmutter, DH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1796-1801
[8]   Safety and Pharmacokinetics of 120 mg/kg versus 60 mg/kg Weekly Intravenous Infusions of Alpha-1 Proteinase Inhibitor in Alpha-1 Antitrypsin Deficiency: A Multicenter, Randomized, Double-Blind, Crossover Study (SPARK) [J].
Campos, Michael A. ;
Kueppers, Friedrich ;
Stocks, James M. ;
Strange, Charlie ;
Chen, Junliang ;
Griffin, Rhonda ;
Wang-Smith, Laurene ;
Brantly, Mark L. .
COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2013, 10 (06) :687-695
[9]   Polyethylene glycol conjugation at Cys232 prolongs the half-life of α1 proteinase inhibitor [J].
Cantin, AM ;
Woods, DE ;
Cloutier, D ;
Dufour, EK ;
Leduc, R .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2002, 27 (06) :659-665
[10]   Intrapleural Administration of an AAVrh.10 Vector Coding for Human α1-Antitrypsin for the Treatment of α1-Antitrypsin Deficiency [J].
Chiuchiolo, Maria J. ;
Kaminsky, Stephen M. ;
Sondhi, Dolan ;
Hackett, Neil R. ;
Rosenberg, Jonathan B. ;
Frenk, Esther Z. ;
Hwang, Yihharn ;
Van de Graaf, Benjamin G. ;
Hutt, Julie A. ;
Wang, Gensheng ;
Benson, Janet ;
Crystal, Ronald G. .
HUMAN GENE THERAPY CLINICAL DEVELOPMENT, 2013, 24 (04) :161-173